Alessandro Bertero - PI

Alessandro Bertero is a group leader at the Molecular Biotechnology Center of the University of Turin, and an Associate Professor in the Department of Molecular Biotechnology and Health Sciences.

- Elisa Balmas PhD, Staff Scientist
- Kirsten Snijders PhD, Postdoc
- Łukasz Truszkowski PhD, Postdoc
- Lù Casini PhD, Postdoc
- Federica Sozza MSci, PhD Student
- Sveva Bottini MSci, PhD Student
- Giulia Savorè MSci, PhD Student
- Silvia Becca MSci, PhD Student
- Maria Luisa Ratto MSci, PhD Student
- Giuseppe Giannino MD, PhD Student
- Sara Bianchi, Bachelor Student
- Irene Ricca, Bachelor Student
Research activity
Our long term vision is improving human sustainable wellbeing. We work to achieve this goal through the integrative application of stem cell biology, gene editing, genomics, and bioengineering to: (1) elucidate the genetic underpinnings of cardiac disease, the #1 killer worldwide; (2) develop regenerative medicine therapy for congenital heart disease, the most common life-threatening malformation in newborns; and, last but not least, (3) provide a cell-based alternative to factory farming, the main cause of biodiversity loss and a central contributor to climate change. These seemingly distinct aspects are actually deeply interconnected: elucidating the gene regulatory mechanisms behind cardiac development and disease provides the knowledge needed to develop cells and tissues for heart remuscularization, which in turn can be produced in even larger scale from animal cells for human consumption. Overall, our work has the potential to improve human life on earth from a holistic perspective: cradle to table and all the way to rocking chair. Our key achievements to date in these three major areas include: (1) elucidating the role of cis and trans nuclear architecture dynamics during both normal heart development and in the pathogenesis of inherited disease (Bertero et al, Nat Commun 2019; Bertero et al JCB 2019); (2) reducing the arrhythmogenic risk of cardiac remuscularization with human pluripotent stem cell-derived cardiomyocytes (patent pending; collaboration between the UW Heart Regeneration Program and Sana Biotechnology); and (3) developing a technology to efficiently and cheaply reprogram pluripotent stem cells into differentiated progenies (patent WO2018096343A1), enabling applications both in the drug screening and cell therapy fields (i.e. bit.bio), and in cellular agriculture (i.e. Meatable). Our current focus is the role of three-dimensional chromatin organization in heart development and disease. We are also building novel genetic tools to probe the structure-function relationship of chromatin compartmentalization. Our work mainly relies on genetic engineering with CRISPR/Cas9, differentiation of human pluripotent stem cells into cardiomyocytes (hPSC-CMs), generation of 3D-engineered heart tissues,determination of nuclear architecture and function with genomic and imaging assays, and analysis of cardiac physiology. Why the et al.? We are immensely worried about the future of our planet in the face of rapidly advancing climate and ecological disasters due to unsustainable human activities. Besides striving for a more sustainable way to do research (i.e recycle and reuse) and travel (i.e. minimize and carbon offset emissions), we place what know-how we have to the service of climate defense. In this light, we wish to try helping combat climate change through cellular agriculture.
2023 – 28 ERC Starting Grant (PI) | European Research Council
2023 – 25 PRIN PNRR 2022 & PRIN 2022 (PI & coPI) | Ministry for University and Research, IT
2022 – 25 FEBS Excellence Award (PI) | Federation of European Biochemical Societies
2022 – 25 AV Single Ventricle Research Fund (PI) | Additional Ventures, USA
2021 – 26 GAHF Career Development Award (PI) | Giovanni Armenise-Harvard Foundation, USA
2020 – 24 NIH R01 (co-I then sub-awardee) | National Institutes of Health, USA
- Bottini S, Bertero A. Growth factor-free stem cell expansion and differentiation. Application No. 102024000013144, filed on 10/06/2024, Ufficio Italiano Brevetti e Marchi (UIBM). Assignee: University of Torino.
- Sozza F, Bertero A. Cell differentiation through multimodal tuning of gene expression. Application No. 102024000013126, filed on 10/06/2024, Ufficio Italiano Brevetti e Marchi (UIBM). Assignee: University of Torino.
- Murry CE, Marchianò S, Reinecke H, Bertero A. Electrophysiological modification to suppress arrhythmias. International Patent Application: PCT/US2022/027382, filed on 03/05/2022. Assignee: University of Washington
- Vallier L, Kotter M, Pawlowski M, Bertero A, Ortmann D. Controllable transcription. European Patent: EP3545079B1; US Patent: US11697823B2, filed on 24/11/2016. Assignee: Cambridge Enterprise Limited
(*co-frst; #co-senior; @correspondence)
- Hirstov BH, Noble WS, Bertero A@ (2024). Systematic identification of inter-chromosomal interaction networks supports the existence of RNA factories. Genome Research, 34, 1610-1623
- Sorge M@, Savoré G, … [8 authors], Balmas E, Raimondi A, Nattenberg G, … [15 authors], Tarone, G., Bertero A#, Brancaccio M#@ (2024). An intrinsic mechanism of metabolic tuning promotes cardiac resilience to stress. EMBO Molecular Medicine, 16, 2450-85
- Truszkowski L*, Bottini S*, Bianchi S, …[7 authors], Balmas E, Elton C, Bertero A@ (2024). Refined home-brew media for cost-effective, weekend-free hiPSC culture and genetic engineering. Open Research Europe doi:10.12688/openreseurope.18245.1
- Marchiano S, … [26 authors], Bertero A#, Murry CE#,@ (2023). Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy. Cell Stem Cell 30, 396-414
- Bertero A, … [10 authors], Murry CE@ (2019). Chromatin compartment dynamics in a haploinsufficient model of cardiac laminopathy. Journal of Cell Biology 218, 2919-44
- Bertero A*, Fields PA*, ... [7 authors], Murry CE@ (2019). Dynamics of genome reorganization during human cardiogenesis reveal an RBM20-dependent splicing factory. Nature Communications 10, 1538
- Bertero A*, Brown S*, .. [14 authors], Vallier L@ (2018). The SMAD2/3 interactome reveals that TGFβ controls m6A mRNA methylation in pluripotency. Nature 555, 256–9
- Pawlowski M*,@, Ortmann D*, Bertero A*, … [3 authors], Kotter MRN@ (2017). Inducible and Deterministic Forward Programming of Human Pluripotent Stem Cells into Neurons, Skeletal Myocytes, and Oligodendrocytes. Stem Cell Reports 8, 803–12
- Bertero A*,@, Pawlowski M*, Ortmann D*, … [15 authors], Vallier L@ (2016). Optimized inducible shRNA and CRISPR/Cas9 platforms for in vitro studies of hu man development using hPSCs. Development 143, 4405–18
- Bertero A, ... [8 authors], Mendjan S#, Pauklin S#, and Vallier L#,@ (2015). Activin/Nodal signaling and NANOG orchestrate human embryonic stem cell fate decisions by controlling the H3K4me3 chromatin mark. Genes & Development 29, 702–17